Skip to main content

Table 1 Results of univariate and multivariate analyses of oncologic outcomes

From: Efficacy of perioperative chemotherapy for synovial sarcoma: a retrospective analysis of a Nationwide database in Japan

Characteristics Number HR (95% CI) P-value HR (95% CI) P-value
Overall survival   Univariate analysis Multivariate analysis
 Sex (male < female) 153/163 0.70 (0.42–1.08) 0.104   
 Age (Over 40 < Under 40) 141/175 0.56 (0.35–0.91) 0.019 0.61 (0.38–0.99) 0.043
 FNCLCC grade (3 < 2) 304/12 0.68 (0.09–4.93) 0.704   
 Subtype (Unclassified < Biphasic) 74/89 0.57 (0.27–1.21) 0.143   
 Subtype (Monophasic < Biphasic) 153/89 0.82 (0.45–1.51) 0.529   
 Depth (Superficial < Deep) 45/271 0.59 (0.24–1.48) 0.263   
 Tumor size (Under 5 cm < Over 5 cm) 117/199 0.73 (0.42–1.29) 0.277   
 Tumor location (Upper < Lower extremity) 56/160 0.81 (0.47–1.41) 0.811   
 Tumor location (Trunk+head and neck < Lower extremity) 100/216 0.81 (0.39–1.68) 0.813   
 Surgical margin (Marginal < Wide) 35/268 0.16 (0.07–0.36) < 0.01 0.18 (0.08–0.38) < 0.01
 Surgical margin (Intralesional < Wide) 13/268 0.29 (0.11–0.79) 0.016 0.30 (0.11–0.78) 0.013
 Adjuvant radiotherapy (Yes < No) 56/260 0.58 (0.32–0.90) 0.018   
 Perioperative chemotherapy (Yes < No) 215/101 0.64 (0.35–1.14) 0.114   
  Neoadjuvant (Yes < No) 165/151 0.73 (0.28–1.88) 0.508   
  Adjuvant (Yes < No) 131/185 0.48 (0.16–1.42) 0.182   
Local control   Univariate analysis Multivariate analysis
 Sex (male < female) 153/163 0.94 (0.42–2.49) 0.940   
 Age (Over 40 < Under 40) 141/175 0.95 (0.39–2.32) 0.910   
 FNCLCC grade (3 < 2)) 304/12 0.05a 0.636   
 Subtype (Unclassified < Biphasic) 74/89 0.58 (0.17–2.70) 0.580   
 Subtype (Monophasic < Biphasic) 153/89 0.82 (0.32–3.12) 0.990   
 Depth (Superficial < Deep) 45/271 0.33 (0.04–2.49) 0.284   
 Tumor size (Under 5 cm < Over 5 cm) 117/199 0.61 (0.22–1.70) 0.340   
 Tumor location (Upper < Lower extremity) 56/160 0.76 (0.28–2.05) 0.592   
 Tumor location (Trunk+head and neck < Lower extremity) 100/216 0.67 (0.17–2.58) 0.557   
 Surgical margin (Marginal < Wide) 35/268 0.12 (0.04–0.36) 0.011 0.14 (0.05–0.44) 0.001
 Surgical margin (Intralesional < Wide) 13/268 0.08 (0.01–0.70) 0.022 0.09 (0.01–0.84) 0.035
 Adjuvant radiotherapy (Yes < No) 56/260 0.24 (0.10–0.58) 0.001   
 Perioperative chemotherapy (Yes < No) 215/101 0.37 (0.12–1.12) 0.171   
  Neoadjuvant (Yes < No) 165/151 0.97 (0.40–2.32) 0.936   
  Adjuvant (Yes < No) 131/185 0.55 (0.20–1.51) 0.248   
Distal recurrent survival   Univariate analysis Multivariate analysis
 Sex (male < female) 153/163 0.60 (0.36–1.01) 0.053 NS  
 Age (Over 40 < Under 40) 141/175 0.56 (0.35–0.90) 0.016 0.63 (0.39–1.03) 0.06
 FNCLCC grade (3 < 2)) 304/12 0.43 (0.06–3.13) 0.407   
 Subtype (Unclassified < Biphasic) 74/89 0.57 (0.27–1.24) 0.160   
 Subtype (Monophasic < Biphasic) 153/89 0.86 (0.46–1.61) 0.640   
 Depth (Superficial < Deep) 45/271 0.53 (0.21–1.31 0.284   
 Tumor size (Under 5 cm < Over 5 cm) 117/199 0.62 (0.35–1.11) 0.340   
 Tumor location (Upper < Lower extremity) 56/160 0.80 (0.45–2.05) 0.592   
 Tumor location (Trunk+head and neck < Lower extremity) 100/216 0.81 (0.39–1.70) 0.557   
 Postoperative local recurrence (Yes < No) 69/247 0.33 (0.16–0.71) 0.004 0.30 (0.17–0.90) 0.027
 Surgical margin (Marginal < Wide) 35/268 0.21 (0.08–0.54) 0.001 0.31 (0.11–0.85) 0.023
 Surgical margin (Intralesional < Wide) 13/268 0.46 (0.15–1.38) 0.105 0.71 (0.21–2.34) 0.571
 Adjuvant radiotherapy (Yes < No) 56/260 0.44 (0.26–0.73) 0.002   
 Perioperative chemotherapy (Yes < No) 215/101 0.60(0.33–1.08) 0.089   
  Neoadjuvant (Yes < No) 165/151 0.86(0.54–1.40) 0.562   
  Adjuvant (Yes < No) 131/185 0.62(0.37–1.05) 0.073   
  1. CI confidence interval, FNCLCC Fédération Nationale des Centres de Lutte Contre le Cancer
  2. a95% CI was scaled out